BEAM Beam Therapeutics Inc
Price (delayed)
$18.48
Market cap
$1.55B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.58
Enterprise value
$1.42B
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a
Highlights
The debt has contracted by 7% YoY
The EPS has dropped by 190% since the previous quarter and by 166% year-on-year
The net income has dropped by 184% year-on-year and by 162% since the previous quarter
Key stats
What are the main financial stats of BEAM
Market
Valuations
Earnings
Shares outstanding
83.69M
Market cap
$1.55B
Enterprise value
$1.42B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.09
Price to sales (P/S)
23.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.32
Revenue
$63.52M
Gross profit
$63.52M
Operating income
-$415.57M
Net income
-$376.74M
EBIT
-$376.7M
EBITDA
-$345.11M
Free cash flow
-$356.19M
Per share
Balance sheet
Liquidity
EPS
-$4.58
EPS diluted
-$4.58
Free cash flow per share
-$4.33
Book value per share
$8.86
Revenue per share
$0.77
TBVPS
$13.41
Total assets
$1.1B
Total liabilities
$370.28M
Debt
$161.43M
Equity
$733.55M
Working capital
$696.08M
Debt to equity
0.22
Current ratio
4.82
Quick ratio
4.72
Net debt/EBITDA
0.37
Margins
Efficiency
Dividend
EBITDA margin
-543.3%
Gross margin
100%
Net margin
-593.1%
Operating margin
-654.3%
Return on assets
-30.8%
Return on equity
-45.8%
Return on invested capital
-40.5%
Return on capital employed
-40.9%
Return on sales
-593.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BEAM stock price
How has the Beam Therapeutics stock price performed over time
Intraday
4.79%
1 week
-15.65%
1 month
-29.84%
1 year
-39.51%
YTD
-25.48%
QTD
-5.38%
Financial performance
How have Beam Therapeutics's revenue and profit performed over time
Revenue
$63.52M
Gross profit
$63.52M
Operating income
-$415.57M
Net income
-$376.74M
Gross margin
100%
Net margin
-593.1%
The net income has dropped by 184% year-on-year and by 162% since the previous quarter
Beam Therapeutics's operating income has shrunk by 135% YoY and by 127% QoQ
Beam Therapeutics's revenue has plunged by 83% YoY and by 82% from the previous quarter
BEAM's gross profit has dropped by 83% year-on-year and by 82% since the previous quarter
Growth
What is Beam Therapeutics's growth rate over time
Valuation
What is Beam Therapeutics stock price valuation
P/E
N/A
P/B
2.09
P/S
23.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.32
The EPS has dropped by 190% since the previous quarter and by 166% year-on-year
The price to book (P/B) is 66% lower than the 5-year quarterly average of 5.8 and 23% lower than the last 4 quarters average of 2.6
BEAM's equity is down by 25% year-on-year and by 7% since the previous quarter
BEAM's price to sales (P/S) is 100% lower than its 5-year quarterly average of 42645.5 but 80% higher than its last 4 quarters average of 12.7
Beam Therapeutics's revenue has plunged by 83% YoY and by 82% from the previous quarter
Efficiency
How efficient is Beam Therapeutics business performance
The ROE has shrunk by 188% YoY and by 183% QoQ
The company's return on assets has shrunk by 183% QoQ
BEAM's ROIC has shrunk by 179% QoQ
Dividends
What is BEAM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BEAM.
Financial health
How did Beam Therapeutics financials performed over time
The total assets is 198% more than the total liabilities
The total assets has contracted by 24% YoY and by 6% from the previous quarter
Beam Therapeutics's total liabilities has decreased by 23% YoY and by 2.6% QoQ
The debt is 78% less than the equity
BEAM's equity is down by 25% year-on-year and by 7% since the previous quarter
The company's debt to equity rose by 22% YoY and by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.